Acne Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris – Drugs In Development, 2022, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 9, 21, 4, 23, 3 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).

– The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Akaal Pharma Pty Ltd
AMD Therapeutics LLC
Amgen Inc
Amytrx Therapeutics Inc
Annji Pharmaceutical Co Ltd
Arcutis Biotherapeutics Inc
Atacama Therapeutics Inc
Attillaps Holdings Inc
Avecho Biotechnology Ltd
Avicanna Inc
Bausch Health Companies Inc
Biofrontera AG
Biozeus Pharmaceutical SA
Blueberry Therapeutics Ltd
Boston Pharmaceuticals Inc
Botanix Pharmaceuticals Ltd
Boulos and Cooper Pharmaceuticals Pty Ltd
Claritas Pharmaceuticals Inc
Clinuvel Pharmaceuticals Ltd
Cosmo Pharmaceuticals NV
Cutanea Life Sciences Inc
Dermata Therapeutics Inc
Dermavant Sciences Inc
Devonian Health Group Inc
Eligo Bioscience SA
Galephar Pharmaceutical Research Inc
Hoth Therapeutics Inc
Innovation Pharmaceuticals Inc
Journey Medical Corp
Kintor Pharmaceutical Ltd
Lee's Pharmaceutical Holdings Ltd
Lipidio Pharmaceuticals Inc
Lipidor AB
Madam Therapeutics BV
Maruho Co Ltd
Matrisys Bioscience Inc
Mayne Pharma Group Ltd
Melinta Therapeutics Inc
Novabiotics Ltd
Novan Inc
Novartis AG
Ortho Dermatologics Inc
Paratek Pharmaceuticals Inc
Phagelux Inc
PHI Therapeutics Inc
Promius Pharma LLC
Provectus Biopharmaceuticals Inc
Revive Therapeutics Ltd
Riptide Bioscience Inc
Sagimet Biosciences Inc
SaNOtize Research and Development Corp
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Timber Pharmaceuticals Inc
Verge Therapeutics Inc
VYNE Therapeutics Inc
Vyome Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage

Acne Vulgaris – Overview

Acne Vulgaris – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acne Vulgaris – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acne Vulgaris – Companies Involved in Therapeutics Development

Acne Vulgaris – Drug Profiles

Acne Vulgaris – Dormant Projects

Acne Vulgaris – Discontinued Products

Acne Vulgaris – Product Development Milestones

Featured News & Press Releases

Mar 25, 2022: Sun Pharma presents phase 3 data for WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris at the AAD Annual Meeting

Feb 03, 2022: Kintor Pharmaceutical: Voluntary announcement first subject dosing in phase I clinical trial of GT20029 (ar-protac) in the United States

Jan 24, 2022: Kintor Pharmaceutical : Voluntary announcement dosing of first patient for acne vulgaris phase II clinical trial of KX-826 in China

Jan 24, 2022: Kintor Pharma Announced successful dosing of the first patient for acne vulgaris phase II clinical trial of KX-826

Jan 14, 2022: Ascletis doses first participant in Phase II acne oral therapy trial

Dec 17, 2021: Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris

Nov 01, 2021: Sun Pharma announces availability of WINLEVI (clascoterone) cream 1% in the U.S. for topical treatment of acne vulgaris

Oct 05, 2021: VYNE Therapeutics Announces its China partner’s enrollment of first patient in phase 3 study of AMZEEQ in patients with moderate to severe acne

Sep 13, 2021: Voluntary announcement Adapalene Clindamycin Hydrochloride combination gel passing the on site inspection for drug registration in China becoming the third GMP inspection that the company has passed this year

Aug 08, 2021: China NMPA approves Phase II clinical trial of ASC40 for the treatment of patients with Acne

Jul 28, 2021: Kintor Pharmaceutical announces dosing of first batch of subjects in phase I clinical trial of GT20029 in China

Jul 19, 2021: VYNE announces initiation of investigator initiated trial evaluating AMZEEQ (minocycline) with oral isotretinoin in patients with moderate to severe acne

Jul 13, 2021: Hoth Therapeutics announces positive confirmatory results from in vivo model of HT-003 assets as potential treatment against acne

Jul 13, 2021: Kintor Pharmaceutical receives IND clearance by the U.S. FDA for GT20029 to treat androgenetic alopecia and acne

Jun 01, 2021: Almirall receives FDA approval to produce Seysara (sarecycline) at the Sant Andreu de la Barca (Barcelona) plant




Secondary Research

Primary Research

Expert Panel Validation

Contact Us


Frequently asked questions

Acne Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Acne Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Acne Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.